Red light therapy is backed by thousands of peer-reviewed studies, but if you're living with chronic pain, inflammation, or an age-related condition, what matters is whether the science actually holds up when you look closely.
Peer-reviewed research has identified at least 15 distinct biological mechanisms through which red and near-infrared light produces measurable changes in human tissue, from directly increasing energy production inside cells to reducing inflammatory signaling, accelerating tissue repair, and reshaping the gut microbiome. This is the most complete plain-language explanation of those mechanisms available, backed by specific studies you can verify yourself.
More than one in three adults over 65 lives with chronic pain (Lucas & Sohi, NCHS Data Brief No. 518, 2024). Over 32.5 million Americans have osteoarthritis (Osteoarthritis Action Alliance, 2024). Pain is the most common reason for a doctor visit in the United States (Cotler et al., 2015). If you're reading this because you're looking for a better approach to managing a health condition, or because you're skeptical about whether light can really do what people claim, the evidence presented here is for you.
Red light therapy isn't a fringe treatment. It's a scientifically studied medical modality with a global market estimated at over $530 million in 2025 and projected to exceed $1.1 billion by 2033, and growing recognition from major medical institutions. In 2024, the American Medical Association's CPT Editorial Panel approved the first CPT code with "photobiomodulation" in its descriptor (0936T, effective January 1, 2025), establishing a formal pathway toward insurance reimbursement. In July 2025, Alcon acquired LumiThera's photobiomodulation platform for retinal disease, marking the first major medtech acquisition in the PBM space. The FDA has cleared multiple home-use devices as Class II medical devices. And research institutions from Harvard to the Wellman Center for Photomedicine continue to publish new findings on how and why it works.
The formal scientific name for red light therapy is photobiomodulation (PBM). It refers to the use of red light (roughly 600–700 nm wavelength) and near-infrared light (roughly 700–1100 nm) at specific doses to stimulate biological processes in cells and tissues. Throughout this article, we use "red light therapy," "RLT," and "photobiomodulation" interchangeably.
Key Takeaways
- Red light therapy works through at least 15 distinct, scientifically documented biological mechanisms, not a single pathway. These mechanisms range from directly increasing energy production inside cells to reshaping the gut microbiome, reducing inflammatory signaling, and stimulating nerve repair. This multi-pathway action is why the same therapy can benefit conditions as different as joint pain, wound healing, and thyroid dysfunction.
- The strongest evidence is in pain reduction, inflammation control, tissue repair, and exercise recovery, with rapidly growing research in neurological health, gut health, and hormonal balance. Multiple randomized controlled trials and meta-analyses support the use of red light therapy for musculoskeletal pain and inflammation. Newer research areas like gut microbiome modulation and neuroprotection have compelling preclinical and early clinical evidence that is expanding every year.
- Dose matters, and more is not always better. One of the most consistently replicated findings in photobiomodulation research is the biphasic dose response: low-to-moderate doses stimulate healing, while excessive doses can inhibit it. This means that using a well-designed device at the right parameters is essential, and that "blasting" yourself with as much light as possible can actually be counterproductive.
Evidence Rating System
Every mechanism in this article is supported by peer-reviewed research, but not all evidence carries the same weight. These ratings help you evaluate the strength of the science behind each mechanism:
★★★★★ Gold Standard: Multiple human randomized controlled trials, systematic reviews, or meta-analyses.
★★★★ Strong: At least one well-designed human RCT, or multiple controlled human studies with consistent findings.
★★★ Moderate: Human clinical studies combined with strong animal evidence.
★★ Emerging: Rigorous animal studies with early or limited human data. Biological mechanism well-established; clinical confirmation still building.
★ Early-Stage: Cell culture or limited animal studies. Promising but not yet tested in humans.
These ratings reflect the current state of evidence. Many mechanisms rated two or three stars today were rated one star just five years ago. The science is advancing rapidly.
I've been watching this field for a long time now, and the conversation has shifted. We're past debating whether photobiomodulation does something at the cellular level. It does. The evidence across pain, inflammation, tissue repair, thyroid function, even early neurological work, it keeps pointing in the same direction. The same core mechanisms, energy production, inflammation control, repair signaling, show up in study after study from independent groups around the world. That kind of consistency is what builds my confidence in a therapeutic approach. The real clinical question now is dosing and protocols: how do we apply this most effectively for a given patient?— Dr. William Carter, MD
How Red Light Therapy Works at the Cellular Level
Every benefit of red light therapy, the anti-inflammatory effects, the tissue repair, the nerve regeneration, begins with what happens at the cellular level when red or near-infrared photons reach your tissue. Three foundational cellular events set the stage.
Mechanism 1: Cellular Energy Production, Recharging Your Mitochondria
Evidence Rating: ★★★★★ Gold Standard
Cellular energy production is the master mechanism of red light therapy. Every other benefit is, in one way or another, downstream from this one.
Inside nearly every cell in your body are mitochondria, tiny power plants that produce ATP, the molecule your cells use as fuel for virtually everything they do: repairing damage, fighting infection, building new tissue, transmitting nerve signals. When mitochondria are impaired by aging, disease, injury, or chronic inflammation, cells can't do their jobs effectively. Tissues degrade. Healing slows. Pain persists.
Red and near-infrared light is absorbed by a specific enzyme in the mitochondria called cytochrome c oxidase, the cell's primary light-absorbing molecule. When photons hit this enzyme, they accelerate the flow of electrons through the energy production chain, increase oxygen consumption, and boost ATP output.
A landmark 2005 study in The Journal of Biological Chemistry by Wong-Riley et al. demonstrated that LED light at 670 nm and 830 nm restored this enzyme's activity and cellular ATP production in neurons whose energy systems had been shut down by a chemical toxin. The most effective wavelengths matched the absorption peaks of the target enzyme, confirming it as the primary photoreceptor. LED pretreatment also reduced neuronal cell death from cyanide poisoning by 48%.
The strongest direct human evidence comes from Fear et al. (2023), published in Aging Cell. This team used a specialized brain imaging technique to directly measure the rate of ATP production in the brains of older adults before and after transcranial photobiomodulation at 670 nm. Six of seven participants showed improvement after four days of treatment. It was the first study to quantify this effect in living human brain tissue using this methodology.
This process is governed by a biphasic dose response (sometimes called the Arndt-Schulz curve): low doses of light stimulate cellular activity, moderate doses plateau, and excessive doses inhibit or produce negative effects. Hamblin (2018) detailed this pattern in a comprehensive Photochemistry and Photobiology review, and it has been observed across ATP production, cell proliferation, wound healing, and clinical outcomes. The practical takeaway is significant: more light isn't always better, and the therapeutic window matters. A foundational 2009 paper in Dose-Response by Huang et al. documented this biphasic pattern across multiple cell types and outcome measures, establishing it as one of the most consistently replicated phenomena in the field.
This energy-boosting effect isn't limited to a specific tissue type. It occurs in neurons, muscle cells, immune cells, skin cells, bone cells, and gut lining cells, which is the foundational reason a single type of therapy can influence such a wide range of health conditions.
Mechanism 2: Nitric Oxide Release, Blood Flow Improvement, and Vascular Repair
Evidence Rating: ★★★★ Strong
The second major event triggered by light absorption is the release of nitric oxide (NO). Under normal conditions, nitric oxide molecules bind to the same sites on the mitochondrial enzyme where oxygen would normally attach, effectively putting a brake on energy production. When red or near-infrared photons hit these binding sites, they knock the nitric oxide molecules loose, a process called photodissociation.
Two immediate consequences follow. The now-vacant binding sites become available for oxygen, further boosting the cell's energy output. And the freed nitric oxide molecules cross the cell membrane and enter the surrounding tissue, where they trigger vasodilation, the relaxation and widening of blood vessels. This improves local blood flow, lymphatic drainage, and tissue oxygenation.
Keszler et al. (2018) published a key study in Archives of Biochemistry and Biophysics demonstrating the wavelength-dependent release of nitric oxide from cellular reserves by red and near-infrared light, providing a biochemical basis for this mechanism.
The real-time circulatory effects have been measured directly. A randomized controlled study by Gavish et al. (2020) in Lasers in Surgery and Medicine recorded a 27% increase in microcirculatory blood flow during near-infrared light application, which grew to a 54% increase over the post-treatment monitoring period. The study also identified that baseline circulation influenced the magnitude of the response; not all individuals responded equally.
Beyond immediate vasodilation, red light therapy stimulates the formation of entirely new blood vessels, a process called angiogenesis. Cury et al. (2013) demonstrated in a skin flap model that photobiomodulation significantly increased blood vessel formation factors and blood vessel density, improving tissue survival. Tuby et al. (2006) showed similar effects in heart tissue, where PBM produced cardioprotective effects through enhanced new blood vessel formation.
For people with conditions involving compromised blood flow, from diabetic neuropathy to post-surgical healing to cardiovascular disease, these vascular effects are particularly relevant. A 2021 review by Colombo et al. in Biomedicines documented that PBM can directly restore blood vessel function in dysfunctional vessels. And in Lasers in Medical Science, Silva et al. (2025) showed that in an animal model of menopause-related cardiovascular changes, chronic photobiomodulation treatment reversed blood vessel dysfunction, increased nitric oxide levels, and reduced blood pressure to normal levels.
Mechanism 3: Secondary Light Receptors, Opsins, Water, and Ion Channels
Evidence Rating: ★★★ Moderate
For decades, the mitochondrial light-absorbing enzyme was considered the only significant target for photobiomodulation. Recent research has identified at least two additional classes of light-absorbing molecules that contribute to the biological effects of red and near-infrared light.
Opsins and membrane receptors. Opsins are a family of light-sensitive proteins historically associated with vision, but non-visual opsins have been found throughout the body, including in blood vessels, skin, and the brain. Arany (2025) categorized photobiomodulation mechanisms into three distinct pathways in a narrative review for JADA Foundational Science: intracellular (mitochondrial), membrane-level (opsins and ion channels), and extracellular. This framework recognizes that PBM acts through multiple receptor classes simultaneously.
A striking 2014 finding published in the Proceedings of the National Academy of Sciences by Sikka et al. demonstrated that light-sensitive receptors in blood vessel walls mediate light-dependent relaxation. Blood vessels themselves contain photoreceptors that respond directly to light exposure. PBM also modulates heat-sensing and pain-sensing channels, which influence downstream signaling independently from mitochondrial mechanisms.
Nanostructured water as a light absorber. At wavelengths beyond approximately 980 nm, the primary light absorber shifts from the mitochondrial enzyme to water clusters within cells. Sharma et al. (2023) detailed in the Journal of Photochemistry and Photobiology how photon absorption by these water structures creates microscopic temperature gradients that activate heat-sensitive ion channels, triggering calcium entry and downstream signaling cascades. Experimental evidence from Wang et al. (2017) in Biochimica et Biophysica Acta confirmed that 810 nm and 980 nm lasers operate through different mechanisms of action on human stem cells, consistent with the two-absorber model.
These secondary pathways explain why photobiomodulation produces biological effects across a wider range of wavelengths than a single light-absorbing molecule would predict, and why different wavelengths may be optimal for different conditions.
How Red Light Therapy Controls Inflammation and Immune Response
Chronic inflammation is the common thread running through many of the conditions that respond to red light therapy, from osteoarthritis to gut disease to neuropathy. Red light therapy interrupts inflammatory cascading at multiple levels simultaneously. For a deeper dive into the inflammation research specifically, see our complete analysis of red light therapy for inflammation.
Mechanism 4: Inflammatory Signaling Reduction
Evidence Rating: ★★★★★ Gold Standard
Measurable reduction of pro-inflammatory signaling molecules is one of the most clinically reproducible effects of photobiomodulation.
When tissue is damaged or under attack, cells release signaling proteins called cytokines that recruit immune cells and amplify the inflammatory response. In acute injury, this is helpful. In chronic conditions, these signals never turn off, creating a destructive cycle of persistent inflammation. At the same time, the body produces anti-inflammatory signals that act as brakes on inflammation. In chronic disease, the balance tips heavily toward the inflammatory side.
Red light therapy shifts this balance back. The most dramatic demonstration comes from a randomized, double-blind, placebo-controlled trial by Marashian et al. (2022) in Frontiers in Immunology. Hospitalized COVID-19 patients treated with photobiomodulation (620–635 nm LED) showed an 82.5% reduction in one key inflammatory marker and an 82.4% reduction in another compared to baseline over 72 hours. The placebo group showed no decrease or even an increase in these same markers.
In musculoskeletal applications, the results are equally concrete. Tomazoni et al. (2021) ran a triple-blinded RCT published in Lasers in Surgery and Medicine and found that a single session of photobiomodulation significantly reduced a key pain and inflammation mediator in patients with chronic non-specific low back pain compared to placebo. One session, no drugs, measurable reduction.
A central insight about how PBM controls inflammation involves its context-dependent behavior. Hamblin (2017) described this in a comprehensive mechanistic review for AIMS Biophysics: in normal, healthy cells, PBM activates pro-healing signaling pathways. In already-inflamed cells, where inflammatory signaling is driving destructive chronic inflammation, PBM reduces downstream inflammatory markers and restores balance. This context-dependent dual action means PBM can simultaneously stimulate healing in healthy tissue and reduce inflammation in diseased tissue.
A 2026 mechanistic investigation in Cells by Ponnusamy et al. identified a key inflammatory signaling pathway functioning as an essential integrator coordinating PBM-activated healing networks (cell culture and animal study). When researchers blocked this pathway, PBM's downstream healing effects were lost, confirming its central role. Lim et al. (2013) showed complementary results in Photochemistry and Photobiology: 635 nm light reduced inflammatory signaling triggered by bacterial challenge in human gum cells, providing a specific molecular pathway for how PBM dampens inflammation.
Mechanism 5: Immune Cell Reprogramming, From Destruction to Repair
Evidence Rating: ★★★★ Strong
Red light therapy doesn't just reduce inflammatory signals. It physically changes how immune cells behave. The most studied example is macrophage polarization. Macrophages are immune cells that exist on a spectrum between two functional states: M1 (pro-inflammatory, tissue-destroying) and M2 (anti-inflammatory, tissue-repairing). In chronic inflammatory conditions, macrophages get stuck in the destructive state, perpetuating damage even after the original trigger is gone.
Hamblin (2017) documented that PBM reduces markers of the destructive macrophage state and promotes the shift toward repair, in a wavelength- and dose-dependent manner. Work by Fernandes et al. (2015) on activated immune cells showed that both 660 nm and 780 nm laser irradiation reduced inflammatory markers, with effects depending on wavelength and energy density.
The immune effects extend well beyond macrophages. Al Balah et al. (2025) published a comprehensive review in Lasers in Medical Science documenting that PBM modulates multiple immune cell types simultaneously: it reduces excessive immune cell recruitment, influences how the immune system presents threats to its defense cells, and promotes regulatory immune cells that prevent overreaction. The enhancement of these regulatory cells is relevant to autoimmune conditions, where the immune system attacks the body's own tissue.
PBM also suppresses mast cell activation. Mast cells are the immune cells responsible for allergic reactions, histamine release, and much of the swelling and itch associated with inflammatory conditions. Alonso et al. (2021) demonstrated in Lasers in Medical Science that transcutaneous systemic PBM reduced lung inflammation in an asthma model by suppressing mast cell activation and increasing anti-inflammatory signaling. This represents a distinct anti-inflammatory pathway with direct implications for allergic and inflammatory conditions.
Mechanism 6: Oxidative Stress Defense and Antioxidant Activation
Evidence Rating: ★★★★ Strong
Oxidative stress, an imbalance between harmful reactive oxygen species and the body's antioxidant defenses, is a driver of aging, chronic disease, and tissue damage. PBM's relationship with oxidative stress is one of its most nuanced effects, and it mirrors the context-dependent pattern seen in inflammation.
In normal, healthy cells, PBM produces a brief, low-level burst of reactive oxygen species that acts as a signaling molecule, triggering protective responses without causing damage. This small oxidative signal activates the body's master antioxidant defense system, ramping up production of the enzymes that neutralize harmful free radicals.
In cells already under oxidative stress, as in chronic disease, aging, or post-exercise damage, PBM reduces harmful oxidative molecules and strengthens antioxidant capacity. The therapy pushes cells toward balance regardless of direction, stimulating where stimulation is needed and suppressing where suppression is needed.
The human evidence is particularly clean. Tomazoni et al. (2019) ran a human RCT on high-level soccer players, published in Oxidative Medicine and Cellular Longevity. Pre-exercise PBM treatment, compared to placebo, produced significantly increased antioxidant enzyme activity, decreased markers of cellular damage from oxidation, and decreased protein damage markers. A single pre-exercise session, measurable antioxidant benefits in elite athletes.
A systematic review by Dos Santos et al. (2017) in the same journal analyzed PBM's effects on oxidative stress across multiple animal models of muscle injury and confirmed consistent reductions in oxidative damage markers alongside increases in antioxidant enzyme activity across studies using various wavelengths and protocols.
How Red Light Therapy Repairs and Regenerates Tissue
Red light therapy accelerates the physical rebuilding of damaged tissue, from skin wounds to fractured bones to injured nerves. These repair processes depend on three foundational effects of red light therapy: increased cellular energy production, improved blood flow, and reduced inflammation.
Mechanism 7: Tissue Repair, Wound Healing, and Collagen Remodeling
Evidence Rating: ★★★★★ Gold Standard
The use of light to accelerate wound healing was the original discovery that launched the entire field of photobiomodulation in 1967, when Endre Mester observed faster hair growth and wound closure in laser-treated mice. Since then, the evidence has grown to include systematic reviews covering dozens of studies.
A systematic review of 27 experimental studies by Da Rocha et al. (2024) in Cell Biochemistry and Function found that LED-based photobiomodulation stimulated cell proliferation, cell migration, new blood vessel formation, collagen deposition, and inflammatory modulation across all phases of wound healing. The effects occurred in both the inflammatory phase (reducing excessive inflammation) and the growth phase (stimulating new tissue), consistent with PBM's context-dependent behavior.
Red light therapy increases the production of both type I and type III collagen, the structural proteins that form the framework of skin, tendons, ligaments, and bone. It does this partly through activating a key tissue repair signaling pathway. Ponnusamy et al. (2026) demonstrated that PBM-generated signaling molecules activate this pathway, which then triggers downstream cascades that promote tissue repair and regeneration (cell culture and animal study).
Tissue repair also requires careful management of the scaffolding between cells. PBM regulates the balance between the enzymes that break down this scaffolding and the proteins that protect it. In Journal of Biophotonics, Ayuk et al. (2018) found that PBM decreased tissue-breakdown enzymes while increasing protective proteins in stressed skin cells. Genah et al. (2021) confirmed in Biomedicines that near-infrared laser therapy modulated these ratios in cells exposed to inflammatory conditions. This balance is critical for organized collagen rebuilding rather than disorganized scar formation.
A narrative review in Photonics by Shaikh-Kader and Houreld (2022) examined PBM's effects on connective tissue cells across bone, cartilage, and tendon. At appropriate wavelengths and doses, PBM stimulates bone-building cell growth in bone, prevents cartilage degradation and improves tissue organization in cartilage, and increases repair cell activity in tendons.
Mechanism 8: Bone Rebuilding and Mineral Density
Evidence Rating: ★★★ Moderate
Red light therapy stimulates the cells that build bone to proliferate, differentiate, and produce collagen and key bone-building components. It simultaneously inhibits bone-resorbing cell activity through specific wavelength-dependent effects.
Published in Experimental Gerontology, Bossini et al. (2012) demonstrated that 830 nm laser therapy improved bone repair in osteoporotic rats. Both dose groups showed significantly more newly formed bone and better-organized collagen fibers compared to untreated controls, along with increased markers for bone cell development and new blood vessel formation at the repair site.
Shaikh-Kader and Houreld (2022) reviewed the broader evidence base and confirmed that PBM at various wavelengths and energy densities can increase bone-building cell survival, growth, migration, and gene expression in both cell culture and animal models. They noted that PBM promotes bone remodeling, the crucial final step in restoring injured bone, and stimulates the differentiation of stem cells into bone-forming cells.
A 635 nm LED study by Lim et al. (2013) in Lasers in Medical Science demonstrated that specific red light wavelengths can inhibit bone-resorbing cell formation by disrupting the structural scaffolding these cells need to function, potentially slowing bone loss. The clinical implications for conditions like osteoporosis, where bone breakdown outpaces bone formation, are significant, though human trials specifically for bone density are still limited.
Mechanism 9: Stem Cell Activation and Cell Survival
Evidence Rating: ★★★ Moderate
Stem cells, undifferentiated cells that can become specialized tissue types, are the body's reserve repair force. Red light therapy enhances their proliferation, migration, and directed differentiation. Stem cells appear particularly sensitive to PBM because of their high mitochondrial content and dependence on cellular signaling.
De Freitas and Hamblin (2016) documented in a comprehensive IEEE Journal of Selected Topics in Quantum Electronics review that PBM enhances proliferation and differentiation of multiple stem cell types, including mesenchymal stem cells and adipose-derived stem cells. Separately, Wang et al. (2016) showed that blue and green light specifically encouraged bone-cell differentiation of human fat-derived stem cells through calcium signaling and light-gated ion channels, demonstrating that different wavelengths can steer stem cell fate in different directions.
PBM also activates survival pathways that protect cells from dying under stress. In the International Journal of Molecular Sciences, Agas et al. (2021) demonstrated that near-infrared 980 nm light activates a key cellular survival pathway in pre-bone-building cells, increasing anti-death proteins and supporting cell survival. Bathini et al. (2020) identified this same pathway in a Cellular and Molecular Neurobiology systematic review as a key mechanism for PBM's brain-protective effects against neurodegenerative diseases.
Mechanism 10: Nerve Regeneration, Pain Signaling, and Analgesic Effects
Evidence Rating: ★★★★ Strong
Red light therapy influences pain and nerve health through three distinct mechanisms that work simultaneously, making it a uniquely multi-targeted analgesic approach.
Nerve growth factor modulation. PBM increases nerve growth factor, a protein that promotes nerve repair and the proliferation of the support cells essential for nerve regeneration. In the Journal of Neurotrauma, De Oliveira Martins et al. (2013) demonstrated in an animal model that PBM increased nerve growth factor by 53% and simultaneously decreased a separate nerve signaling protein that, when elevated, amplifies pain sensitivity. Pain behavior improved correspondingly. Reducing that pain-amplifying signal is itself therapeutic, a nuanced effect that reflects PBM's context-dependent action.
Martins et al. (2025) synthesized preclinical and clinical evidence in a comprehensive Frontiers in Photonics review and confirmed that PBM acts on multiple neural targets: nerve growth factors, inflammatory signals, ion channels, and structural nerve repair. The review concluded that PBM represents a promising non-pharmacological approach for neuropathic pain conditions.
Selective nerve fiber inhibition. At higher irradiances, PBM can selectively inhibit the small-diameter nerve fibers that transmit pain and heat signals, while preserving large-fiber function. Buzza et al. (2024) showed in Lasers in Surgery and Medicine that this produces a targeted "nerve block" effect through localized disruptions in pain-sensing neurons, reducing energy production and signal transmission at the nerve. This analgesic mechanism is distinct from the anti-inflammatory pathway and can last hours to days.
In The Journal of Pain, Cheng et al. (2021) documented the multiple pathways through which PBM modulates pain: peripheral nerve conduction block, anti-inflammatory modulation, endogenous opioid activation, and central nervous system modulation.
Endogenous opioid activation. Pereira et al. (2017) published a finding in Lasers in Surgery and Medicine that settles whether PBM engages the body's own pain-relief system. PBM-induced pain relief could be blocked by naloxone, a drug that specifically antagonizes opioid receptors. This proves that PBM activates the body's own opioid system, providing a separate analgesic pathway independent of both the anti-inflammatory and nerve-block mechanisms. A systematic review in Photomedicine and Laser Surgery by Bjordal et al. (2006) analyzed possible mechanisms of action across multiple RCTs and confirmed both anti-inflammatory and neural inhibitory mechanisms as contributors to PBM's clinical pain relief.
For a detailed analysis of how these mechanisms apply to specific pain conditions, see our Pain Relief Blog.
Red Light Therapy's Whole-Body and Systemic Effects
Red light therapy also produces effects that go beyond local tissue, reaching the brain, the gut, the endocrine system, and even distant tissues that were never directly exposed to light.
Mechanism 11: Brain Protection, Neurodegeneration Defense, and Cognitive Support
Evidence Rating: ★★★ Moderate
Red light therapy's effects on the brain represent one of the fastest-growing research areas in photobiomodulation. Multiple mechanisms converge to protect neurons, clear toxic proteins, and support cognitive function.
Blood-brain barrier protection. Ma et al. (2025) demonstrated in Alzheimer's Research & Therapy that PBM enhanced blood-brain barrier integrity in an Alzheimer's mouse model by activating a key energy-sensing pathway that strengthened the tight junctions between barrier cells. PBM also facilitated clearance of the toxic amyloid-β protein that accumulates in Alzheimer's disease. When the energy-sensing pathway was experimentally blocked, PBM's protective effects on the barrier were substantially diminished, confirming its critical role.
Toxic protein reduction. In Parkinson's disease, the accumulation of misfolded alpha-synuclein protein destroys dopamine-producing neurons. A 2015 study in PLoS ONE by Oueslati et al. showed that 28 days of 808 nm PBM in a genetic rat model of Parkinson's disease significantly reduced alpha-synuclein accumulation, alleviated motor impairment, and preserved dopaminergic neurons, with benefits sustained at least 6 weeks after treatment ended. This suggests a disease-modifying effect rather than merely symptomatic relief.
Brain waste clearance. The brain's waste clearance system (the glymphatic system) and the meningeal lymphatic system are responsible for removing toxic metabolites. Salehpour et al. (2022) outlined in the International Journal of Molecular Sciences how PBM stimulates these drainage systems through nitric oxide-mediated relaxation of lymphatic vessels. Experimental evidence from Semyachkina-Glushkovskaya et al. (2020) in Biomedical Optics Express confirmed that PBM enhances brain lymphatic clearance, with direct implications for neurodegenerative diseases characterized by toxic protein buildup.
Cortical neural oscillation. Liebert et al. (2023) described in Biomedicines how PBM affects brain wave patterns, including gamma oscillations (30–100 Hz) that are disrupted in neurodegenerative diseases, fibromyalgia, and migraine. They proposed that PBM may restore normal oscillatory patterns, a mechanism independent of the mitochondrial light-absorbing enzyme that expands the explanatory framework for PBM's neurological effects.
Remote neuroprotection. One of the most striking findings in PBM research is that light applied to the abdomen or legs can protect the brain. In the European Journal of Neuroscience, Gordon et al. (2023) demonstrated that PBM applied to the abdomen rescued approximately 80% of dopaminergic neurons in a Parkinson's mouse model, comparable to the neuroprotection achieved by direct transcranial treatment. The mechanism involves circulating mediators: immune cells, stem cells, and/or microbiome-mediated signals that propagate from the irradiated site to distant tissues. This finding has been observed across multiple species, including mice (Gordon et al., 2023), rats (Oueslati et al., 2015), and non-human primates, overturning the assumption that PBM can only benefit tissue it directly reaches.
Mechanism 12: Gut Microbiome Remodeling (Photobiomics)
Evidence Rating: ★★ Emerging
The discovery that red and near-infrared light applied to the abdomen can reshape the gut microbiome has opened an entirely new field that researchers have named photobiomics.
The most compelling evidence comes from Upadhyay et al. (2025), out of the Wellman Center for Photomedicine at Harvard/Massachusetts General Hospital, published in Advanced Science. Brief, non-invasive abdominal PBM (980 nm) preserved gut lining integrity and maintained all seven major gut bacterial groups that intense exercise normally disrupts. It also enriched beneficial bacteria and elevated key beneficial metabolites. Combined abdomen-and-leg PBM nearly doubled time to exhaustion on a graded treadmill test and produced a fourfold increase in energy-producing structures within muscle tissue. The study established that PBM works through both direct mitochondrial effects and indirect gut-microbiome-mediated systemic benefits.
A 2025 PRISMA systematic review by Guimarães et al. in Biomedicines identified nine studies, five in humans and four in animals, applying abdominal PBM and measuring gut-related, metabolic, or neurobehavioral outcomes. Human trials, primarily in Parkinson's and Alzheimer's disease, used 630–904 nm light and reported improvements in mobility, balance, cognition, and olfaction alongside preliminary microbiome changes.
In a case report published in Photobiomodulation, Photomedicine, and Laser Surgery, Bicknell et al. (2022) documented that infrared laser treatment (904 nm) to the abdomen of a human patient produced increases in beneficial gut bacteria, specifically Akkermansia, Faecalibacterium, and Roseburia, genera associated with gut barrier integrity and anti-inflammatory metabolite production.
Cao et al. (2025) published findings in Microorganisms demonstrating that PBM targeted at the gut ameliorated Alzheimer's pathology in an animal model via the gut-brain axis, with efficacy comparable to transcranial irradiation. This connected the gut microbiome mechanism directly to neurological health and supported the concept that the abdomen may be an effective treatment site for brain conditions.
For a complete exploration of this topic, see our in-depth guide to red light therapy for gut health.
Mechanism 13: Muscle Performance, Exercise Recovery, and Delayed-Onset Muscle Soreness
Evidence Rating: ★★★★★ Gold Standard
The use of PBM for exercise performance and recovery is one of the best-studied applications, supported by multiple meta-analyses and RCTs.
Pre-exercise PBM works through metabolic preconditioning: by increasing mitochondrial ATP reserves before exercise begins, it reduces the muscle's dependence on anaerobic energy production, decreases lactate accumulation, and attenuates the post-exercise inflammatory cascade that causes delayed-onset muscle soreness (DOMS).
A meta-analysis of randomized controlled trials by Li et al. (2024) in Lasers in Medical Science confirmed that pre-exercise PBM improves muscle endurance and promotes recovery from muscle strength loss and exercise-induced injuries across people with different activity levels. Ferraresi et al. (2016) documented in the Journal of Biophotonics improvements in time to exhaustion, number of repetitions, peak torque, and reductions in muscle damage and blood lactate across multiple studies.
Tomazoni et al. (2019), in a human RCT on elite soccer players published in Oxidative Medicine and Cellular Longevity, provided direct evidence that pre-exercise PBM simultaneously improved antioxidant defenses, reduced oxidative damage, and attenuated muscle damage markers, demonstrating that the exercise recovery benefits operate through PBM's established oxidative stress defense and anti-inflammatory pathways.
Mechanism 14: Thyroid and Hormonal Balance
Evidence Rating: ★★★★ Strong
Red light therapy has shown particular promise for Hashimoto's thyroiditis, the most common cause of hypothyroidism. The mechanism involves both anti-inflammatory suppression of autoimmune attack on thyroid tissue and direct stimulation of thyroid cell regeneration.
The most important trial in this area is the randomized, placebo-controlled study by Höfling et al. (2012) in Lasers in Medical Science. Forty-three patients with Hashimoto's-induced hypothyroidism received 10 sessions of 830 nm laser therapy. After levothyroxine was withdrawn, the laser-treated group required less than half the medication dose (38.59 μg/day) compared to the placebo group (106.88 μg/day) to maintain normal thyroid function. The laser group also showed reduced thyroid antibodies, a direct marker of autoimmune attack, and improved thyroid tissue appearance on ultrasound.
A six-year follow-up study (Höfling et al., 2018) confirmed that the laser-treated group continued to require significantly less thyroid medication than the placebo group, with a higher proportion maintaining normal thyroid volume. The authors noted that periodic retreatment may optimize long-term outcomes, consistent with the therapy's role as an ongoing management tool for autoimmune thyroid disease.
Erçetin et al. (2020) reported in Photobiomodulation, Photomedicine, and Laser Surgery that PBM improved the T3/T4 conversion ratio and quality of life in Hashimoto's patients. Berisha-Muharremi et al. (2023) found in a clinical trial published in the Journal of Personalized Medicine that PBM combined with supplements was more effective than supplements alone in restoring thyroid function over a 6-month follow-up.
For cardiovascular and hormonal health beyond the thyroid, Silva et al. (2025) showed that chronic PBM treatment reversed blood vessel dysfunction and blood pressure increases that occur with estrogen loss, suggesting direct relevance for menopausal cardiovascular changes. For more on how red light therapy supports women's hormonal health, see our Wellness Blog.
Mechanism 15: Fat Cell Metabolism and Body Composition
Evidence Rating: ★★ Emerging
Red light therapy activates mitochondria specifically within fat cells, triggering a cascade of metabolic changes. Modena et al. (2022, 2023) demonstrated in studies published in the Journal of Cosmetic and Laser Therapy and Lasers in Medical Science that PBM activated mitochondrial energy pathways and fat-breakdown processes in human adipose tissue samples from obese women. The treated tissue showed significant activation of mitochondrial restructuring pathways, processes that lead to fat breakdown and fat cell death. These effects were observed in actual human clinical tissue, not just cell cultures.
While this mechanism is well-characterized at the cellular level, large-scale clinical trials specifically measuring fat loss outcomes in humans are still limited. The evidence is promising but should be considered emerging until confirmed by additional controlled human studies.
What Has Not Been Fully Tested
Transparency about limitations is as important as presenting the evidence.
Most PBM research has been conducted at specific wavelengths (typically 630–670 nm and 800–850 nm), specific doses, and specific treatment durations. Results at one set of parameters don't automatically apply to different parameters. The biphasic dose response means that more isn't always better.
The gut microbiome research (Mechanism 12) has produced consistent directional findings across animal models and small human studies, but controlled human trials with microbiome composition as a primary endpoint haven't yet been published. This is a rapidly developing area where the preclinical evidence has outpaced clinical confirmation, a normal pattern in translational science.
In the Höfling thyroid studies, the antibody reduction and vascularization improvement observed at nine months didn't persist at the six-year follow-up, and the absolute medication dose in the laser group gradually increased over time. The persistent advantage over the placebo group reflected both a residual treatment effect and progressive disease worsening in untreated patients. The authors recommend periodic retreatment to maintain optimal results.
The Marashian et al. COVID-19 cytokine study, while showing dramatic reductions in inflammatory markers, was sized as a pilot trial to detect signal rather than confirm efficacy. Independent replication with larger cohorts will strengthen the evidence.
Most studies on autoimmune conditions (thyroid, inflammatory bowel disease) involve relatively small sample sizes. The results are consistently positive and mechanistically coherent, but independent replication with larger cohorts will strengthen the evidence further.
PBM is a complement to, not a replacement for, appropriate medical care. People with serious health conditions should work with their healthcare providers to determine whether red light therapy is an appropriate addition to their treatment plan.
Is Red Light Therapy Right for You?
The biological case for red light therapy is built on 15 distinct, peer-reviewed mechanisms operating across every major tissue type in the body. It's a multi-pathway intervention that enhances cellular energy, reduces inflammation, accelerates tissue repair, modulates the immune system, supports nerve and brain health, and reshapes the gut microbiome.
The people most likely to benefit are those dealing with chronic pain and inflammation (especially musculoskeletal conditions), anyone recovering from injury or surgery, people with neuropathy or nerve-related conditions, those with thyroid autoimmunity, athletes seeking faster recovery and reduced muscle soreness, and individuals managing age-related health decline.
The evidence is strong in some areas and still building in others, and this article has been transparent about which is which. You now have the information to decide for yourself whether red light therapy is worth exploring for your situation.
